VivoSeq
Other

Arsenic Trioxide

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Arsenic Trioxide is an early-stage landscape with 0 programs across 1 company. The most active players are SDK Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SDK Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed6 · 38%
Unknown status5 · 31%
Terminated2 · 13%
Withdrawn1 · 6%
Recruiting1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Frontline Oral Arsenic Trioxide for APL
Recruiting·TThe University of Hong Kong·Phase 2·NCT04687176·100 enrolled
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
Not yet recruiting·SSDK Therapeutics, Inc.·Phase 3·NCT07296445·120 enrolled
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Completed·NNew Mexico Cancer Research Alliance·Phase 2·NCT00250042·6 enrolled
Arsenic Trioxide in Treating Men With Germ Cell Cancer
Completed·SWOG Cancer Research Network·Phase 2·NCT00036842
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Completed·OOrsenix LLC·Phase 1·NCT03048344·12 enrolled
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT01428128·50 enrolled
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00661544·48 enrolled
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT00195104·87 enrolled
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT00582400·9 enrolled
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
Terminated·NNantes University Hospital·Phase 2·NCT01738360·11 enrolled
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Withdrawn·—·Phase 1·NCT02699723
Oral Arsenic Trioxide for NPM1-mutated AML
Unknown status·TThe University of Hong Kong·Phase 2·NCT04689815·50 enrolled
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
Unknown status·GGuangzhou 8th People's Hospital·Phase 1·NCT03980665·20 enrolled
Arsenic Trioxide for Structural p53 Mutations
Unknown status·SShanghai Changzheng Hospital·Phase 2·NCT04695223·30 enrolled
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
Unknown status·RRuijin Hospital·Phase 1·NCT03855371·5 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)